OBJECTIVE To examine the safety, tolerability, and reproducibility of intraocular pressure (IOP) patterns during repeated continuous 24-hour IOP monitoring with a contact lens sensor. METHODS Forty patients suspected of having glaucoma(n=21) or with established glaucoma (n=19) were studied.Patients participated in two 24-hour IOP monitoring sessions (S1 and S2) at a 1-week interval (SENSIMED ...

glaucoma is the second leading cause of irreversible blindness and a neurodegenerative disease with a complex pathogenesis. increasing evidence suggests that oxidative stress and mitochondrial dysfunction have crucial roles in most neurodegenerative diseases such as glaucoma. the conventional clinical treatment for glaucoma is lowering the intraocular pressure (iop). some patients have normal i...

BACKGROUND There is an increasing body of evidence strongly suggesting that glaucoma medications may contribute to ocular surface disease and development of dry eye. OBJECTIVE To identify glaucoma patients with dry eye, using a nationally representative sample, and to compare clinical and treatment characteristics with controls without dry eye. METHODS Patients taking intraocular pressure-l...

BackgroundApproximately half of glaucoma patients have dry eye disease (DED) due to anti-glaucoma medication use. Herein, we evaluated the effectiveness self-retained cryopreserved amniotic membrane (AM) in managing glaucoma-induced DED.
 MethodsA retrospective chart review was conducted on consecutive treated with AM (Prokera Slim, BioTissue, Miami, FL) for ocular surface induced by chron...

PURPOSE To understand the factors that influence glaucoma treatment adherence with medication taking, prescription refills, and appointment keeping to develop an intervention for a specific population. PATIENTS AND METHODS In-depth interviews were conducted with 80 individuals diagnosed with open-angle glaucoma, glaucoma suspect, or ocular hypertension. Additional eligibility requirements wer...

PURPOSE To develop methods for investigating adherence to glaucoma medications by using a modified claims data-based measure of adherence, validation by chart review, and patient and physician interviews. METHODS Data from administrative claims of 13,956 subjects receiving an initial glaucoma medication, and data from overlapping samples of 300 patients' charts, 300 interviews of patients, an...

BACKGROUND Glaucoma is one of the leading causes of blindness. Reduction of intraocular pressure is the only proven way to prevent progression of glaucomatous optic neuropathy. The majority of glaucoma patients need to use antiglaucoma ophthalmic solutions over the course of their life. Thus, good adherence and persistency of glaucoma treatment are important factors for better glaucoma care. ...